Tuesday, July 26, 2022 Daily Archives

Lenti of deals: Oxford Biomedica inks two agreements

by

Oxford Biomedica’s LentiStable technology will be used by Orchard Therapeutics to develop investigational HSC therapy, OTL-203. The firm will also license its LentiVector platform to an undisclosed company for its lead CAR-T program. According to Oxford Biomedica, Orchard Therapeutics will use its LentiStable technology platform to develop a producer cell line with the ability to express lentiviral vectors. In particular, the project will focus specifically on progressing candidate clones of OTL-203, a gene therapy that aims to potentially treat mucopolysaccharidosis…

July 26, 2022

Danaher dismisses biotech funding crunch as it rides the late-stage wave

by

Danaher is confident it will continue to see high-single to low-double digit growth within its Pall and Cytiva bioprocess businesses, despite concerns surrounding dips in biotech funding and reduced COVID-related revenue. For the second quarter 2022, Danaher Corporation reported revenues of $7.8 billion, up 9.5% on the same period last year. The company does not breakdown its results by business but during a financial call last week divulged its bioprocessing division “continued to see record activity levels” driving a combined…

July 26, 2022

Cell and gene sector could benefit from synthetic standards for flow cytometry

by

Cell and gene therapy developers need better ways of validating flow cytrometry software according to researchers who say synthetic datasets could help improve product quality. The comments were included in a study published in March that looked at the current state of flow cytometry data analysis tools used in the cell and gene therapy. The key finding was that the lack of standard validation methods means many manufacturers rely on subjective assessments. “Characterization of ATMPs by automated flow cytometry data…

July 26, 2022